Azenta (Azenta) Risk Assessment

View and export this data going back to 1995. Start your Free Trial

What is Azenta Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Azenta is: High Risk: Sensitive to economic or industry trends.

Competitive Comparison of Azenta's Risk Assessment

For the Medical Instruments & Supplies subindustry, Azenta's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Azenta's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Azenta's Risk Assessment falls into.

Azenta (NAS:AZTA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Azenta Risk Assessment Related Terms

Thank you for viewing the detailed overview of Azenta's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Azenta (Azenta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

BA3:Germany

Address

200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803

Website

https://www.azenta.com

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

Executives

Herman Cueto	officer: EVP, Chief Financial Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes	officer: VP, Chief Accounting Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray	officer: Chief Strategy & New Business	C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin	director
Dorothy E Puhy	director	DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne	officer: SVP and GM, Life Sciences Proj	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou	officer: SVP and General Manager, Genom	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus	officer: EVP & Chief Operating Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson	officer: EVP & Chief Financial Officer	C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley	officer: Chief Human Resources Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram	officer: VP, Finance & Corp. Controller	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De	officer: Chief Commercial Officer, LS	15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka	officer: Sr. VP, General Manager	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha	officer: SVP, GM BLS-Products	15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824